Globus Medical, Inc. (GMED) Stock Analysis
A live, multi-source view of Globus Medical, Inc. (GMED): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Globus Medical, Inc.
Globus Medical, Inc. develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products comprising traditional fusion implants, such as pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices; treatment options for motion preservation technologies consisting of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and biologic solutions, such as allografts and synthetic alternatives. It also provides orthopedic trauma solutions, including limb reconstruction, fracture plating, intramedullary nailing, external fixation, and compression screw technologies; hip and knee arthroplasty solutions, including modular cement and cementless hip stems, acetabular cups, femoral heads, highly cross-linked liners, partial knee systems, cruciate retaining, posterior stabilized, and revision options; spinal cord stimulation services; and neuromonitoring services, which provide onsite and remote monitoring of the neurological systems.
Sector: Healthcare · Industry: Medical Devices · United States · 6,000 employees · globusmedical.com
Key statistics · as of 2026-09-05
As of 2026-09-05, Globus Medical, Inc. (GMED) had a market capitalization of $10.51B, a trailing P/E of 20.0 (forward 14.5) and a beta of 0.96; the shares traded in a 52-week range of $54.15 – $101.40 (31.5% over the year).
- Market cap
- $10.51B
- Enterprise value
- $10.03B
- Trailing P/E
- 20.0
- Forward P/E
- 14.5
- PEG ratio
- 1.49
- Price / book
- 2.20
- EPS (trailing)
- $3.91
- EPS (forward)
- $5.40
- Payout ratio
- 0.0%
- 52-week range
- $54.15 – $101.40
- 52-week change
- 31.5%
- Beta
- 0.96
- Average volume
- 1.6M
- Shares outstanding
- 111.8M
- Short % of float
- 6.13%
- Profit margin
- 17.0%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-11
In RapidTradeView’s 2026-09-11 scan of the US universe, Globus Medical, Inc. (GMED) last closed at $73.56 (the last completed close before that scan).
Technicals at the scan: RSI 29 (oversold territory), price -10.4% versus its 20-day average, 20-day versus 50-day average spread +2.0%, MACD histogram -1.27.
Sentiment inputs: 83% of recent Finnhub-scored headlines read bullish; StockTwits 100% bullish; analyst consensus score 72/100.
Next scheduled company event: in 55 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 0 buys and 0 sells of GMED; corporate insiders filed 0 buys and 1 sell (1 filer, latest disclosure 2026-08-19). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: Stephen T. Zarrilli (0B/1S). Who is trading what
RapidTradeView pick record
GMED has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Globus Medical, Inc. (GMED) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell GMED.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.